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Angiogenesis, the process of new blood vessel 
formation from existing vessels, plays an im-
portant role in normal physiology (Tonnesen 
et al., 2000), as well as in many pathological 
conditions including cancer (Folkman, 1971; 
Papetti and Herman, 2002), macular degenera-
tion (Ahmad et al., 2011), and various vascular 
diseases (Khurana et al., 2005). Strikingly, in-
creased angiogenesis is observed in many types 
of  human  cancers  (Bergers  and  Benjamin, 
2003; Dvorak, 2003), whereas angiogenesis 
is decreased in age-associated vascular diseases 
(Ungvari et al., 2010). Therefore, diseases that 
are  associated  with  increased  angiogenesis, 
such as human cancers, can be treated by inhib-
iting angiogenesis (Folkman, 2007). In contrast, 
stimulation of angiogenesis could be beneficial   
in the treatment of coronary artery disease and 
other vascular diseases characterized by insuffi-
cient blood flow to target organs as a result of 
blocked or damaged blood vessels (Khan et al., 
2002; Al Sabti, 2007). Many factors that influence 
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The incidence of human papillary thyroid cancer (PTC) is increasing and an aggressive 
subtype of this disease is resistant to treatment with vascular endothelial growth factor 
receptor 2 (VEGFR2) inhibitor. VEGFR2 promotes angiogenesis by triggering endothelial  
cell proliferation and migration. However, the molecular mechanisms governing VEGFR2 
stability in vivo remain unknown. Additionally, whether VEGFR2 influences PTC cell migration  
is not clear. We show that the ubiquitin E3 ligase SCF-TRCP promotes ubiquitination and 
destruction of VEGFR2 in a casein kinase I (CKI)–dependent manner. -TRCP knockdown 
or CKI inhibition causes accumulation of VEGFR2, resulting in increased activity of signaling 
pathways downstream of VEGFR2. -TRCP–depleted endothelial cells exhibit enhanced 
migration and angiogenesis in vitro. Furthermore, -TRCP knockdown increased angiogenesis 
and vessel branching in zebrafish. Importantly, we found an inverse correlation between  
-TRCP protein levels and angiogenesis in PTC. We also show that -TRCP inhibits cell 
migration and decreases sensitivity to the VEGFR2 inhibitor sorafenib in poorly differentiated 
PTC cells. These results provide a new biomarker that may aid a rational use of tyrosine 
kinase inhibitors to treat refractory PTC.
© 2012 Wei et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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more  targeted  subgroup  of  patients  to  efficiently  suppress 
thyroid tumor growth, migration, and angiogenesis through 
inhibiting VEGFR2 functions.
Ubiquitin-mediated proteolysis plays an important role in 
the regulation of many cellular processes by facilitating the 
timely destruction of key regulatory proteins by the 26S pro-
teasome complex (Ciechanover et al., 2000). SCF-TRCP is a 
well characterized E3 ubiquitin ligase that is involved in the 
degradation of many proteins involved in cell signaling and 
cell cycle regulation (Liu et al., 1999; Busino et al., 2003; 
Watanabe et al., 2004). Furthermore, -TRCP, a substrate 
recognition subunit of SCF-TRCP, has a prominent role in 
breast cancer, as it regulates prolactin receptor levels in a pro-
teasome-dependent manner (Li et al., 2006). This type of 
ligand-stimulated receptor degradation is one of the mecha-
nisms that are involved in negative regulation of several 
growth factor receptors, including EGFR, PDGFR, and 
CSFR1, which belong to the family of receptor tyrosine   
kinase (Schlessinger, 2000). This degradation process is mainly 
initiated by the addition of ubiquitin moieties after receptor 
engagement, which then targets the ubiquitinated receptors 
to the lysosomal/proteasomal machineries for proteolysis. 
It has been reported that the carboxyl terminus of VEGFR2 
is required for ligand-dependent activation of VEGFR2 sig-
naling as well as PKC-mediated down-regulation of VEGFR2 
(Meyer et al., 2004; Singh et al., 2005). A recent study indicated 
the involvement of a PEST motif in the down-regulation of 
VEGFR2 protein (Meyer et al., 2011). However, the molec-
ular mechanisms of VEGFR2 degradation, as well as the sig-
nificance of this pathway in controlling angiogenesis in vivo, 
still remain unknown. Here we report that the SCF-TRCP 
E3 ligase plays a key role in regulating angiogenesis, through 
modulating  VEGFR2 stability and the activities of VEGFR2 
downstream signaling pathways. Our results also offer the 
molecular understanding and the rationale for targeted use 
of sorafenib to treat thyroid cancer patients with relatively 
low -TRCP protein expression levels.
RESULTS
VEGFR2 stability is controlled by -TRCP
Multi-subunit Cullin–Ring complexes comprise the largest 
known class of E3 ubiquitin ligases (Petroski and Deshaies, 
2005). Cullins directly interact with Roc1, a Ring finger pro-
tein, and the Cullin–Roc1 complex comprises the core mod-
ule of a series of E3 ubiquitin ligases. Thus, we started our 
investigation by examining whether a specific Cullin–Ring 
complex interacts with VEGFR2. We found that Cullin 1, 
but not other members of the Cullin family that we examined, 
specifically interacts with VEGFR2 (Fig. 1, A and B). This 
suggests  that  the  SCF  complex,  which  contains  Cullin  1, 
might be involved in the regulation of VEGFR2 stability. In 
keeping with this notion, depletion of endogenous Cullin 1, 
but not Cullin 4A, resulted in the up-regulation of VEGFR2 
expression in human microvascular endothelial cells (HMVECs; 
Fig. 1 C). Next, we sought to explore which F-box protein, 
when complexed with Cullin 1, is responsible for VEGFR2 
angiogenesis have been identified; however, the molecular 
mechanisms by which angiogenesis is regulated are still not 
fully understood. Therefore, identifying the mechanisms that 
regulate blood vessel formation would be beneficial in treat-
ing various diseases associated with angiogenesis defects.
Vascular endothelial growth factor (VEGF) is one of the 
most potent proangiogenic growth factors involved in the 
regulation of angiogenesis (Brown et al., 1997; Ferrara, 1999). 
Although there are three types of VEGF receptors, VEGF   
receptor 2 (VEGFR2; also named KDR or Flk1) is the prin-
cipal receptor that transmits VEGF-A signals in vascular 
endothelial cells, which subsequently results in enhanced an-
giogenesis (Shibuya and Claesson-Welsh, 2006). The critical 
role of VEGFR2 in vascular development is highlighted by 
the fact that VEGFR2/ mice die at embryonic days 8.5–
9.5 (E8.5–9.5) as a result of defective development of endo-
thelial cells and blood islands (Shalaby et al., 1995). Recent 
studies revealed that VEGFR2 also plays a major role in 
tumor angiogenesis as well as in tumor growth (Fong et al., 
1999). Moreover, VEGF-A is also secreted by a variety of 
human and rodent tumor cell lines (Senger et al., 1983, 1986), 
and VEGFR2 is overexpressed in many cancers including 
colon (Takahashi et al., 1995), gastric (Zhang et al., 2002), lung 
(Seto et al., 2006), breast (Kranz et al., 1999), and thyroid 
cancer (Bunone et al., 1999; Vieira et al., 2005; Rodríguez-
  Antona et al., 2010). These expression patterns of VEGFR2 
and VEGF-A suggest the existence of both paracrine and   
autocrine signaling between tumor cells and vascular endo-
thelial cells, which contribute to pathological angiogenesis 
and tumor growth (Alitalo and Carmeliet, 2002; Shibuya and 
Claesson-Welsh, 2006).
Although elevated levels of VEGFR2 are detected in thy-
roid tumors (Vieira et al., 2005; Rodríguez-Antona et al., 
2010), the molecular mechanisms for such elevation and its 
contribution to the development of thyroid tumor, whose 
incidence is increasing more rapidly than other types of 
human cancers around the world (Leenhardt et al., 2004; Davies 
and Welch, 2006), still remain largely unknown. Interest-
ingly, the VEGFR2 inhibitor sorafenib, a multi–tyrosine   
kinase inhibitor (TKI), has been recently used in clinical trials 
as an anti–thyroid tumor therapy (Cohen et al., 2008; Gupta-
Abramson et al., 2008; Kloos et al., 2009; Sherman, 2011). 
However, the molecular mechanism underlying the usage of 
sorafenib to treat thyroid tumors, as well as the critical con-
tribution of VEGFR2 in thyroid tumors, remains largely 
unknown. Moreover, recent clinical trials with sorafenib in 
patients with aggressive/metastatic forms of thyroid cancers 
showed only a partial response rate, suggesting that these 
aggressive tumors may elicit unknown resistance mechanisms 
to this drug (Gupta-Abramson et al., 2008; Cabanillas et al., 
2010). Therefore, identifying the molecular mechanisms by 
which VEGFR2 is regulated in both endothelial cells and 
cancer cells will shed new light on how physiological angio-
genesis is regulated and how dysfunction in these pathways 
leads to pathological angiogenesis and tumorigenesis. This 
knowledge will guide the clinical application of TKIs to a JEM Vol. 209, No. 7 
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Figure 1.  VEGFR2 stability is controlled by SCF-TRCP. (A) Immunoblot analysis of WCLs and immunoprecipitates (IP) derived from 293T cells transfected with 
HA-VEGFR2 and various Myc-tagged Cullin constructs or EV. Data shown is representative of two independent experiments. (B) Immunoblot analysis of HMVEC 
WCLs and anti-VEGFR2 immunoprecipitates. Mouse IgG was used as a negative control for the immunoprecipitation procedure. Data shown is representative of 
two independent experiments. (C) Immunoblot analysis of HMVECs infected with the shRNA constructs specific for GFP or the indicated Cullin constructs. Data 
shown is representative of two independent experiments. (D) Immunoblot analysis of immunoprecipitates and WCL derived from 293T cells transfected with  
HA-VEGFR2 and/or Myc-tagged -TRCP1, -TRCP2, or -TRCP1 (R474A) constructs. Data shown is representative of two independent experiments. (E) Immunoblot 
analysis of HMVEC WCLs and anti-VEGFR2 immunoprecipitates. Mouse IgG was used as a negative control for the immunoprecipitation procedure. Data shown is 
representative of two independent experiments. (F) Immunoblot analysis of WCL and immunoprecipitates derived from 293T cells transfected with HA-VEGFR2 and 
Myc–-TRCP1 constructs as indicated. Where indicated, cell lysates were pretreated with -phosphatase before the immunoprecipitation procedure. Data shown 
is representative of two independent experiments. (G) Immunoblot analysis of WCL from 293T and HeLa cells transfected with shRNA constructs specific for GFP or 
-TRCP1, -TRCP2, or -TRCP1+2. Data shown is representative of two independent experiments. (H) 293T cells were transfected with the indicated shRNA  
constructs. 20 h after transfection, cells were split into 60-mm dishes. 20 h later, cells were treated with 20 µg/ml CHX. At the indicated time points, WCLs 
were prepared, and immunoblots were probed with the indicated antibodies. Data shown is representative of three independent experiments. (I) Quantification of 
the band intensities in H. VEGFR2 band intensity was normalized to tubulin, and then normalized to the t = 0 controls. The error bars represent mean ± SD (n = 3).1292 -TRCP triggers VEGFR2 turnover | Wei et al.
with VEGFR2 (Fig. 2 E). Consistent with this finding, de-
pletion of endogenous CKI, but not other CKI isoforms 
(CKI and CKI), led to a significant increase in endoge-
nous  VEGFR2  abundance  (Fig.  2  F).  Consistent  with  a 
negative role of CKI in VEGFR2 stability control, deple-
tion of CKI significantly extended endogenous VEGFR2 
half-life in HMVECs (Fig. 2, G and H). In a reciprocal set of 
experiments, we found that overexpression of CKI markedly 
decreased the half-life of VEGFR2 (Fig. 2 I).
CKI phosphorylates VEGFR2 at both DSG and DDTD 
phosphodegrons to promote its interaction with -TRCP1
Most -TRCP substrates contain one or several DSG(XX)S 
degrons that are recognized by -TRCP when they are prop-
erly phosphorylated by one or more kinases (Frescas and 
Pagano, 2008). We noticed that there are three DSG(XX)S 
degrons present in the C-terminal tail of VEGFR2 that are 
conserved among different species (Fig. 3 A; and Fig. S1, A–C). 
Interestingly, most of the Ser/Thr sites within the putative 
degrons are predicted to be CKI sites (Fig. S1, E and F). To 
test the significance of each putative phosphodegron, we cre-
ated individual point mutations in the DSG motifs by replac-
ing both serine residues with alanine to examine whether 
these mutants resist CKI-mediated VEGFR2 degradation 
(Fig. 3 A). We found that individual mutation of each DSG 
motif (labeled DSG1, DSG2, and DSG3) had no significant 
effect on -TRCP–mediated destruction of VEGFR2 in the 
presence of CKI (Fig. 3 B), suggesting that the phosphoryla-
tion of all three DSG degrons might be involved in the deg-
radation of VEGFR2. To test this hypothesis, we generated a 
DSG triple mutant that contains serine to alanine substitu-
tions in all three DSG degrons (labeled as DSG-T). However, 
VEGFR2–DSG-T could still be degraded by -TRCP1/
CKI with similar efficiency (Fig. 3 E). Furthermore, the 
half-life of DSG-T was not significantly increased in response 
to  VEGF-A (unpublished data), indicating that there are other 
potential degrons present in VEGFR2 mediating its destruc-
tion. Using the ScanSite program, we identified another po-
tential CKI phosphorylation site (DDTD) in the C-terminal 
tail of VEGFR2 (Fig. 3 A and Fig. S1 F). Thus, we generated 
additional  VEGFR2 mutants (Fig. 3 A) to evaluate the contri-
bution of the DDTD site in -TRCP–mediated VEGFR2 
destruction. Using in vitro kinase assays, we showed that the 
three identified DSG sites, as well as the newly identified 
DDTD site, are the major CKI phosphorylation sites. Com-
binational inactivation of the three DSG degrons (DSG-T), 
or DDTD alone, significantly reduced CKI-mediated phos-
phorylation of  VEGFR2 (Fig. 3 C). Moreover, combinational 
mutation of all four putative degrons (9A) further decreased 
CKI-mediated in vitro phosphorylation of GST-VEGFR2 
(Fig. 3 C). Consistent with this result, CKI treatment trig-
gered the interaction between GST-VEGFR2 and -TRCP1 
in vitro (Fig. 3 D). In contrast, mutation of the three putative 
DSG degrons (DSG-T) led to a reduced interaction between 
GST-VEGFR2 and -TRCP1. Interestingly, mutation of 
all four degrons (9A) led to further reduction in detectable 
degradation. -TRCP, one of the well characterized F-box 
proteins, binds to its substrates by recognizing a specific 
DSG(XX)S phosphodegron motif, within which the two ser-
ine residues are phosphorylated (Frescas and Pagano, 2008). 
We noticed that the cytoplasmic tail of VEGFR2 contains 
three DSG(XX)S motifs that could potentially be recognized 
by -TRCP and are conserved among different species (see 
Fig. 3 A). This prompted us to examine whether -TRCP 
interacts with VEGFR2 in vitro. Using coimmunoprecipita-
tion, we found that both -TRCP1 and -TRCP2 interact 
with VEGFR2 (Fig. 1 D). The interaction between VEGFR2 
and -TRCP1 was abolished when the C-terminal WD40 
repeat motif of -TRCP1, which has been shown to mediate 
the interaction with most of its substrates (Wu et al., 2003), 
was mutated (Fig.1 D). Furthermore, we detected an inter-
action between endogenous VEGFR2 and endogenous   
-TRCP1 in HMVECs (Fig. 1 E) and further demonstrated 
that phosphatase treatment abolished the interaction between 
VEGFR2 and -TRCP1 (Fig. 1 F). In support of an impor-
tant role for -TRCP in regulating VEGFR2 abundance, de-
pletion of either -TRCP1 or -TRCP2 led to up-regulation 
of VEGFR2 levels (Fig. 1 G). More importantly, depletion 
of -TRCP did not affect significantly VEGFR2 mRNA 
levels (see Fig. 4 D), suggesting that the observed increase in 
VEGFR2 abundance was mainly through posttranscriptional 
mechanisms. In support of this notion, using cycloheximide, 
we demonstrated that the half-life of VEGFR2 was markedly 
extended after depletion of -TRCP1 (Fig. 1, H and I).
Casein kinase I (CKI) is involved in the regulation  
of VEGFR2 protein stability
It has been demonstrated that -TRCP substrates need to be 
phosphorylated within their degron sequences by specific ki-
nases before their recognition and destruction by the SCF-TRCP 
complex (Jin et al., 2003; Cardozo and Pagano, 2004). We 
therefore sought to identify the upstream kinase that phos-
phorylates VEGFR2 and triggers its destruction. To this end, we 
transfected 293T cells with HA-VEGFR2 and Flag–-TRCP1, 
along with different kinases (CKI [Inuzuka et al., 2010] and 
GSK3 [Liu et al., 2002]) that have been previously identified 
to play a critical role in facilitating -TRCP–mediated prote-
olysis of the target protein. CKI, but not GSK3, promoted 
the destruction of ectopically expressed VEGFR2 (Fig. 2 A). 
Furthermore,  this  degradation  of  VEGFR2  was  completely 
blocked when treated with the proteasome inhibitor MG132, 
suggesting the involvement of 26S proteasome (Fig. 2 A). Im-
portantly, the R474A mutant form of -TRCP1 that is im-
paired to interact with VEGFR2 (Fig. 1 D) failed to promote 
VEGFR2 destruction by CKI (Fig. 2 B), suggesting a critical 
role of -TRCP1 in CKI-mediated destruction of VEGFR2.
In further support of a direct role of CKI in VEGFR2 
protein stability, VEGFR2 levels were markedly up-regulated 
in a concentration-dependent manner when HMVECs were 
treated with D4476, a specific CKI inhibitor (Fig. 2, C and D). 
Furthermore, coimmunoprecipitation analysis revealed that 
CKI, but not CKI or CKI isoforms, specifically interacts JEM Vol. 209, No. 7 
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Figure 2.  CKI is involved in the regulation of VEGFR2 stability. (A) Immunoblot analysis of 293T cells transfected with HA-VEGFR2, Flag–-TRCP1, and 
indicated kinases. Where indicated, cells were treated with the proteasome inhibitor MG132. Data shown is representative of two independent experiments.  
(B) Immunoblot analysis of 293T cells transfected with HA-VEGFR2 and/or Myc-CKI together with Flag-WT–-TRCP1 or Flag-R474A–-TRCP1. Data shown is 
representative of two independent experiments. (C and D) Immunoblot analysis of HMVECs treated with the CKI inhibitor D4476 at the indicated concentrations 
for 12 h. In D, where indicated, 100 ng/ml VEGF-A was added for 2 h before harvesting. Data shown is representative of two independent experiments.  
(E) Immunoblot analysis of WCLs and immunoprecipitates (IP) derived from 293T cells transfected with HA-VEGFR2 and Myc-tagged versions of indicated CKI 
isoforms. Data shown is representative of two independent experiments. (F) Immunoblot analysis of HMVECs infected with shRNA specific for GFP or the  
indicated CKI isoforms. Data shown is representative of two independent experiments. (G) HMVECs were transfected with the indicated shRNA constructs.  
40 h after infection, cells were treated with 1 µg/ml puromycin for 72 h to eliminate the noninfected cells. Afterward, the resulting cells were split into 60-mm 
dishes and, after another 20 h, were treated with 20 µg/ml CHX. At the indicated time points, WCLs were prepared, and immunoblots were probed with the indicated 
antibodies. Data shown is representative of three independent experiments. (H) Quantification of the band intensities in G. VEGFR2 band intensity was normal-
ized to tubulin, and then normalized to the t = 0 controls. The error bars represent mean ± SD (n = 3). (I) 293T cells were transfected with EV or a construct 
encoding CKI. 20 h after transfection, cells were split into 60-mm dishes, and after another 20 h cells were treated with 20 µg/ml CHX. At the indicated time 
points, WCLs were prepared, and immunoblots were probed with the indicated antibodies. Data shown is representative of two independent experiments.1294 -TRCP triggers VEGFR2 turnover | Wei et al.
interactions with -TRCP1, these mutants are also deficient 
in -TRCP1/CKI–mediated proteolysis (Fig. 3 E). Impor-
tantly,  compared  with WT-VEGFR2,  9A-VEGFR2  could 
interaction between GST-VEGFR2 and -TRCP1 (Fig. 3 D), 
which reflects their deficiency in CKI-mediated phosphory-
lation (Fig. 3 C). Moreover, consistent with their decreased 
Figure 3.  Phosphorylation of VEGFR2 by CKI at multiple sites triggers its ubiquitination and degradation by SCF-TRCP. (A) Illustration of VEGFR2 
protein and various VEGFR2 mutants generated for this study. There are three DSG degrons present in the C-terminal tail of VEGFR2 that can be identified 
by -TRCP1. AA represents two alanines substituted from two serines in DSG1, DSG2, and DSG3 degrons (Fig. S1, A–C). AAA represents three alanines 
substituted from three threonines in the DDTD degron (Fig. S1 D). (B) Immunoblot analysis of 293T cells transfected with the indicated HA-VEGFR2 and 
Flag–-TRCP1 plasmids in the presence or absence of Myc-CKI. Where indicated, cells were treated with the proteasome inhibitor MG132. Data shown is 
representative of two independent experiments. (C) Purified CKI protein was incubated with 5 µg of the indicated glutathione S-transferase (GST)–VEGFR2 
fusion proteins in the presence of -[32P]ATP. The protein kinase reaction products were resolved by SDS-PAGE, and phosphorylation was detected by 
autoradiography. Top: autoradiogram of phosphorylated GST-VEGFR2; bottom panel: staining of GST-VEGFR2 to demonstrate equal loading. Data 
shown is representative of two independent experiments. Black lines indicate that intervening lanes were spliced out. (D) Autoradiograms show a recovery 
of 35S-labeled -TRCP1 protein bound to the indicated GST-VEGFR2 fusion proteins (GST protein as a negative control) incubated with CKI before 
pulldown assays. Top: autoradiogram of -TRCP1 bound with GST-VEGFR2; bottom: staining of GST-VEGFR2 to demonstrate equal loading. Data shown is 
representative of two independent experiments. Black lines indicate that intervening lanes were spliced out. (E) Immunoblot analysis of 293T cells trans-
fected with the indicated HA-VEGFR2 and Flag–-TRCP1 plasmids in the presence or absence of Myc-CKI. Data shown is representative of two indepen-
dent experiments. (F) Immunoblot analysis of WCL from 293 cells transfected with indicated constructs. Where indicated, cells were treated with 100 ng/ml 
VEGF-A for 2 h before harvesting. Data shown is representative of two independent experiments. (G) Affinity-purified SCF-TRCP complexes were incubated 
with purified recombinant GST-VEGFR2 proteins, purified E1 and E2, and ubiquitin as indicated at 30°C for 45 min. The ubiquitination reaction products 
were resolved by SDS-PAGE and probed with the anti-VEGFR2 antibody. Data shown is representative of two independent experiments.JEM Vol. 209, No. 7 
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similarly activate the downstream ERK signaling pathway   
(Fig. 3 F) and promote cell migration in a  VEGF-A–dependent 
manner (unpublished data), indicating that 9A-VEGFR2 is 
functional in vivo. We further showed that -TRCP1 promotes 
in vitro VEGFR2 ubiquitination in a CKI-dependent manner 
(Fig. 3 G) and that the inefficient destruction of 9A-VEGFR2 
observed in Fig. 3 E is likely a result of deficient ubiquitination 
of VEGFR2 (Fig. 3 G).
Depletion of -TRCP increases VEGFR2 protein levels, 
VEGF-A–induced signaling, cell migration, and enhanced 
tube formation in HMVECs
Because VEGFR2 is predominantly expressed in endothelial 
cells and is involved in the regulation of angiogenesis, we 
next investigated whether depletion of endogenous -TRCP 
affects VEGFR2  protein  abundance  in  HMVECs  under 
physiological conditions. Depletion of either -TRCP1   
or -TRCP1+2 in HMVECs (Fig. 4, B and C) led to up-
  regulation of VEGFR2 protein levels (Fig. 4 A). In contrast, 
depletion of endogenous -TRCP did not affect the expres-
sion of other VEGF receptors (VEGFR1 and VEGFR3) or 
CCM3, a protein recently reported to modulate VEGFR2 
function (Fig. 4 A; He et al., 2010). Furthermore, -TRCP 
depletion did not affect cell viability compared with shGFP 
control cells (unpublished data). These results suggest that 
-TRCP  might  regulate  angiogenesis  through  specifi-
cally targeting VEGFR2 for ubiquitination and destruc-
tion. Furthermore, -TRCP depletion did not cause a marked 
change in VEGFR2 mRNA levels (Fig. 4 D), suggesting that 
-TRCP regulates VEGFR2 expression mainly through a 
Figure 4.  -TRCP regulates VEGFR2 protein levels in HMVECs. (A) Immunoblot analysis of HMVECs stably expressing lentiviral vectors encoding 
shRNA specific for GFP, -TRCP1, and -TRCP1+2. Data shown is representative of two independent experiments. (B and C) Real-time RT-PCR analysis  
of -TRCP1 (B) and -TRCP2 (C) mRNA expression in HMVECs infected with the indicated shRNA lentiviral vectors. Error bars indicate mean ± SD from 
three independent experiments. ***, P < 0.001. (D) Real-time RT-PCR analysis of VEGFR2 mRNA expression in HMVECs infected with the indicated shRNA 
lentiviral vectors. Error bars indicate mean ± SD from three independent experiments. (E) HMVECs were infected with the indicated shRNA lentiviral  
vectors. After selection with 1 µg/ml puromycin for 72 h, cells were split into 60-mm dishes and, after another 20 h, treated with 20 µg/ml CHX.  
At the indicated time points, WCLs were prepared, and immunoblots were probed with the indicated antibodies. Data shown is representative of three 
independent experiments. (F) Immunoblot analysis of the HMVECs shown in A, stimulated where indicated with 100 ng/ml VEGF-A for 15 min.  
Data shown is representative of two independent experiments.1296 -TRCP triggers VEGFR2 turnover | Wei et al.
More  importantly,  we  found  that 
depletion of -TRCP results in in-
creased  activity  of VEGFR2  down-
stream signaling pathways as indicated 
by increased p-VEGFR2 (pTyr1175), 
p-AKT  (pSer473),  and  p-ERK1/2 
levels (Fig. 4 F; Shibuya and Claesson-
Welsh, 2006).
Consistent with the role of -TRCP 
in regulating VEGFR2 abundance and 
the activities of downstream signal-
ing pathways, compared with shGFP-
  treated  HMVECs,  -TRCP–depleted 
HMVECs  exhibited  increased  migra-
tion (Fig. 5, A and B). Furthermore, 
using in vitro angiogenesis (matrigel 
tube formation) assays, we found that 
depletion  of  endogenous  -TRCP 
in  HMVECs  leads  to  a  significant 
increase in their capacity to form tubes as compared with con-
trol cells infected with shGFP (Fig. 5, C and D).  VEGF-A addi-
tion significantly increased the number of tubes in shGFP cells; 
posttranscriptional mechanism. Consistently, the half-life of 
endogenous VEGFR2 was increased in -TRCP–depleted 
HMVECs  compared  with  shGFP-treated  cells  (Fig.  4  E). 
Figure 5.  -TRCP regulates endothelial 
cell migration and angiogenesis in vitro. 
(A) HMVECs were exposed to 30 ng/ml  
VEGF-A where indicated. Recruited cells  
were photographed after 5 h. Bars, 10 µm. 
Data shown is representative of three inde-
pendent experiments. (B) Quantitative  
measurement of cell migration shown in  
A. The error bars represent mean ± SD.  
***, P < 0.001; n = 3. (C) HMVECs shown in A 
were subjected to a Matrigel tube formation 
assay in the presence or absence of 100 ng/ml 
VEGF-A and photographed after 5 h. Bars, 
10 µm. Data shown is representative of 
three independent experiments.  
(D) Quantitative measurement of tubes formed  
in C. The error bars represent mean ± SD.  
*, P < 0.05; ***, P < 0.001; n = 3. (E) Immuno-
blot analysis of the HMVECs infected  
with the indicated shRNA lentiviral vectors. 
Data shown is representative of two inde-
pendent experiments. (F) HMVECs shown in 
E were exposed to 100 ng/ml VEGF-A  
where indicated. Recruited cells were  
photographed after 5 h. Bars, 10 µm. Data 
shown is representative of two independent 
experiments. (G) Immunoblot analysis of 
the HMVECs infected with HA--TRCP1 
where indicated. Data shown is represen-
tative of two independent experiments.  
(H) HMVECs shown in G were subjected  
to a Matrigel tube formation assay in the 
presence or absence of 100 ng/ml VEGF-A 
and photographed after 5 h. Bars, 10 µm. 
Data shown is representative of two inde-
pendent experiments.JEM Vol. 209, No. 7 
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relationship between loss of -TRCP and elevated   
in vitro tube formation in HMVECs.
Because both enhanced cellular migration and   
elevated in vitro tube formation are positive markers 
for increased angiogenesis, these results support a po-
tential role for -TRCP in regulating the angiogenesis 
process through modulating VEGFR2 stability. How-
ever, we recognize that the in vitro cell-based assays 
may not accurately model the angiogenesis process under phys-
iological conditions. To obtain direct evidence to support the 
potential role of -TRCP in regulation of angiogenesis, we 
used a well characterized in vivo zebrafish model (Nasevicius   
et al., 2000; Habeck et al., 2002) to evaluate how -TRCP 
governs VEGFR2 stability to influence angiogenesis.
-TRCP2 depletion leads to increased expression  
of VEGFR2 and in vivo angiogenesis in zebrafish
It has been previously demonstrated that both VEGF-A and 
VEGFR2 are required for vasculogenesis in zebrafish (Nasevicius 
et al., 2000; Habeck et al., 2002). Loss of VEGF-A function 
however, VEGF-A addition did not increase the number of 
tubes either by sh-TRCP1 or sh-TRCP1+2 cells (Fig. 5, 
C and D), suggesting that because these cells already have in-
creased ability to form tubes, further addition of VEGF-A did 
not increase tube formation in sh-TRCP cells. Furthermore, 
additional depletion of VEGFR2 blocked the elevated tube 
formation in -TRCP–depleted HMVECs, indicating that 
VEGFR2 may be the major route through which -TRCP 
regulates the tube formation ability of HMVECs (Fig. 5,   
E and F), while reintroducing -TRCP into the -TRCP–
  depleted HMVECs retarded their in vitro tube formation 
(Fig. 5, G and H). These results therefore indicate a causal 
Figure 6.  Inactivation of -TRCP2 leads to VEGFR2 up-
regulation and increased angiogenesis in zebrafish in vivo. 
(A and B) Vascular development in control (A) or 20 µM MO  
(B)-treated KdrI:EGFP embryos. MO was used to deplete both 
Fbxw11a and Fbxw11b. Images were taken by fluorescence  
microscopy at 72 h postfertilization (hpf). Bars, 50 µm. Data 
shown is representative of three independent experiments.  
(C and D) Close-up images of blood vessel formation in the 
head/anterior trunk of zebrafish treated with control (C corre-
sponds to the blue-boxed regions of A) or Fbxw11a and  
Fbxw11b MOs (D corresponds to the blue-boxed regions of B). 
Yellow arrows in C point to junction areas where normal  
mirror-paired intersomitic vessel development was observed, 
whereas red arrows in D point to areas of excess/disorganized 
branching of intersomitic vessels. Bars, 50 µm. Data shown is 
representative of three independent experiments. (E and F) 
Close-up images of blood vessel formation in the posterior 
trunk/tail of zebrafish treated with control (E corresponds to  
the red-boxed regions of A) or Fbxw11a and Fbxw11b MOs  
(F corresponds to the red-boxed regions of B). Yellow arrows in  
E point to junction areas where normal mirror-paired inter-
somitic vessel development was observed, whereas red arrows in  
F point to areas of excess/disorganized branching of intersomitic 
vessels. Bars, 50 µm. Data shown is representative of three inde-
pendent experiments. (G) RT-PCR analysis of endogenous 
Fbxw11a and Fbxw11b mRNA levels in MO-treated zebrafish  
compared with sibling controls (C). Data shown is  
representative of three independent experiments. (H) VEGFR2 
protein expression was analyzed by Western blot in control  
(C) and -TRCP2–MO-treated zebrafish embryos. Data shown is 
representative of two independent experiments. (I and J) Close-
up images of blood vessel formation in the red-boxed region in 
the posterior trunk/tail of zebrafish treated with combination 
treatment of splice MO against Fbxw11a and Fbxw11b. Red  
arrows point to areas of excess/ disorganized branching of  
intersomitic vessels observed after depletion of both Fbxw11a 
and Fbxw11b. Bars, 50 µm. Data are representative of three  
independent experiments.1298 -TRCP triggers VEGFR2 turnover | Wei et al.
that the -TRCP1/2 double knockout mice are nearly 
normal, with severe defects in spermatogenesis caused by the   
stabilization of SNAIL. As the authors used sh-TRCP2 to 
knock down endogenous -TRCP2 in the -TRCP1/ 
mice  background  to  achieve  the  -TRCP1/2  double 
knockout phenotype, it is possible that the residual expres-
sion of -TRCP2 allows the sh-TRCP2/-TRCP1/ 
mice to function relatively normally. Further studies are   
required to explore whether deletion of -TRCP1 and/or 
-TRCP2 in mice also results in abnormalities in angio-
genesis and vascular development.
-TRCP suppresses VEGFR2 abundance to inhibit human 
thyroid cancer and endothelial cell migration, desensitizing 
human thyroid cancer cells to sorafenib treatment
Thyroid cancer accounts for up to 95% of primary cancers 
involving the endocrine system. Papillary thyroid cancer 
(PTC) is the most common type of thyroid cancer, represent-
ing 75–85% of all thyroid cancer cases, and various signaling 
pathways, such as BRAF and MAPK (i.e., ERK1/2), have 
been identified as participants in the initiation and progres-
sion of human PTC (Khurana et al., 2005; Knauf and Fagin, 
2009; Nucera et al., 2009, 2010; Keefe et al., 2010; Liu et al., 
2010;  Chakravarty  et  al.,  2011).  Importantly,  as  in  many 
other human cancers, VEGFR2-induced angiogenesis was 
found to play a critical role in thyroid cancer angiogenesis 
(Keefe et al., 2010; Ringel, 2011). In keeping with this no-
tion, recent clinical trials have proposed VEGFR inhibitors, 
such as axitinib and sorafenib, as anti-thyroid cancer thera-
peutics (Cohen et al., 2008; Gupta-Abramson et al., 2008), 
although the underlying mechanism of their therapeutic 
effects remains unknown. This prompted us to further examine 
whether -TRCP negatively governs  VEGFR2 stability in the 
human thyroid cancer, and furthermore, whether de-regulation 
of this destruction pathway contributes to the pathological pro-
gression of human thyroid cancers. In keeping with our 
hypothesis, we observed a robust inverse correlation between 
-TRCP1 and VEGFR2 protein expression levels in the 
human thyroid cancer cell lines we examined (Fig. 7, A and B). 
In contrast to SW1736 and 8505C anaplastic thyroid cancer 
(ATC)–derived cell lines, or the FTC236 metastatic follicular 
cancer–derived cell line (Fig. 7, A and B), which display high 
expression of -TRCP1, the human BCPAP cell line, a 
poorly differentiated PTC with squamous metaplasia-derived 
cell line, has very low -TRCP1 protein expression and ele-
vated VEGFR2 protein expression levels (Fig. 7 A). In sup-
port of this result, we also detected an inverse correlation 
between -TRCP1 protein expression levels and angiogenic 
profile (i.e., CD31 immunoexpression) in an array of poorly 
or well differentiated human PTC with squamous metaplasia 
foci (Table S1), which were similar to the initial tumor from 
which the BCPAP cell line was established (Fig. 7 C). In par-
ticular, we found that 50% of PTC with squamous meta-
plasia showed high expression levels (3+) of -TRCP1, both 
in the cytoplasm of tumor cells or in the endothelial cells, and 
low/moderate CD31 (1+/2+) or absent VEGFR2 protein 
severely affects the formation of the entire vasculature, whereas 
VEGFR2 dysfunction impairs the formation of blood vessels 
generated by sprouting (Nasevicius et al., 2000; Habeck et al., 
2002). Thus, we sought to examine whether inactivation of 
-TRCP by morpholino (MO) treatment affects vasculo-
genesis and/or angiogenesis in zebrafish. Interestingly, zebra-
fish does not contain a homologue of human -TRCP1 but 
contains two paralogues of -TRCP2 (called Fbxw11a and 
Fbxw11b). Embryos injected with control or MOs specifi-
cally inactivating Fbxw11a or Fbxw11b alone or in combina-
tion were monitored for alterations in blood vessel formation 
over 72 h after fertilization. Although a small dose-dependent 
decrease of embryo viability was observed with either the 
Fbxw11a or Fbxw11b MO alone, at the highest concentra-
tion (100 µM) injected, >90% of the zebrafish embryos were 
still viable (Fig. S2). In contrast, combinatorial MO injec-
tion significantly reduced embryo viability, such that at a   
concentration  of  100  µM,  100%  lethality  was  observed. 
Combinatorial low-dose MO injection (20 µM) resulted   
in reduced viability compared with controls (61.5%) but   
allowed the embryos to develop with overall normal gross 
morphology allowing analysis (Fig. S2). These data indicate 
that there is partial functional redundancy between the two 
-TRCP2 paralogues.
To further characterize the potential role of -TRCP2 in 
angiogenesis, we used the low-dose (20 µM) combinatorial 
MO strategy to simultaneously inactivate both Fbxw11a and 
Fbxw11b during zebrafish vascular development in two endo-
thelial reporter lines: Kdrl:EGFP (Fig. 6, A–F; Cross et al., 2003) 
and  fli1a:EGFP  (unpublished  data;  Lawson  and Weinstein, 
2002). Whereas large blood vessels such as the dorsal aorta 
appeared to form normally, -TRCP2–MO-injected em-
bryos exhibited dysregulated vessel formation with increased 
sprouting as compared with controls (Fig. 6, A and B). Fine 
analysis of the head/anterior trunk (blue boxed region) 
and posterior trunk/tail (red boxed region; Fig. 6 C–F) 
demonstrates that compared with the normal blood vessel 
formation observed in the control embryos (Fig. 6, C and E, 
yellow arrows), there is a significant increase in the number of 
branching blood vessels initiated in -TRCP2–MO-treated 
zebrafish (Fig. 6, D and F, red arrows). Significantly, unlike the 
symmetrical pairs of vessels formed at regular intervals along 
the somite boundaries in controls, in -TRCP2–MO-injected 
embryos vascular sprouts were commonly disorganized, orig-
inating at several points along the length of each somite, or 
with multiple branching connections converging at a single 
point. These results were confirmed by in situ hybridization 
(unpublished data), as well as combinatorial splice-blocking 
MOs, demonstrating the specificity of the effect and signifi-
cant  reduction  of  gene  expression  of  both  Fbxw11a  and 
Fbxw11b RT-PCR (Fig. 6 G) compared with uninjected 
sibling controls. This elevated blood vessel development was 
found to correlate with increased expression of VEGFR2 
(Fig. 6, H–J) after MO-mediated knockdown of -TRCP2 
(Fig. 6 G), consistent with our in vitro data using HMVECs. 
However, it was recently reported by Kanarek et al. (2010) JEM Vol. 209, No. 7 
Article
1299
PTC-associated endothelial cells/high-powered fields express 
VEGFR2 (Fig. 7 C).
Importantly, ectopic expression of -TRCP1 led to a 
significant reduction in the endogenous VEGFR2 abundance 
expression levels (Fig. 7, C and D). Whereas PTC with low 
-TRCP1 protein expression levels (1+) showed increased 
intratumoral angiogenesis (CD31 immunoexpression; Fig. 7, 
C and D), and intriguingly 6% of PTC cells and 40% of 
Figure 7.  -TRCP regulates VEGFR2 protein levels in human poorly differentiated PTC-derived cells. (A and B) Immunoblot analysis of various 
human thyroid cancer cell lines with indicated antibodies. Data are representative of two independent experiments. (C) Human PTC with squamous meta-
plasia (SM) were stained with the indicated antibodies and analyzed by immunohistochemistry. Low -TRCP is defined as 1–10% of endothelial or human 
PTC cells with SM foci being positive for -TRCP staining. High -TRCP is defined as >50% of endothelial or human PTC cells with SM being positive for 
-TRCP. H+E, H&E staining. Bars: (400×) 200 µm; (1,000×) 50 µm. Arrows and arrowheads highlight endothelium and tumor cells, respectively. (D) Quan-
titative measurement of the microvascular density (as defined by number of vessels per field showing CD31 staining in PTC samples expressing low or 
high amounts of -TRCP1) shown in C. The error bars represent mean ± SD. ***, P < 0.001 (n = 3). (E and F) Immunoblot analysis of BCPAP cells infected 
with either EV or HA–-TRCP1-encoding lentiviral vectors. Where indicated, cells were treated with the proteasome inhibitor MG132. Data are represen-
tative of two independent experiments. (G and H) Real-time RT-PCR analysis of VEGFR2 (G) and -TRCP1 (H) mRNA in BCPAP cells infected with EV or 
HA--TRCP1–encoding lentiviral vectors. Data are representative of three independent experiments. The error bars represent mean ± SD. ***, P < 0.001.1300 -TRCP triggers VEGFR2 turnover | Wei et al.
BCPAP-EV cells; Fig. 8 B). Ectopic 
expression of -TRCP1 did not af-
fect the mRNA levels of VEGF-A 
(unpublished data), indicating that 
-TRCP1 might regulate VEGF-A 
through a posttranscriptional mech-
anism. Whereas additional investiga-
tion is warranted to uncover the molecular mechanisms 
underlying the effect of -TRCP1 on secretion of VEGF-A, 
we found that VEGF-A contains an evolutionally conserved 
DSG-like phosphodegron (Fig. S3), suggesting an interesting 
possibility that -TRCP1 may regulate the stability of VEGF-A 
precursor to indirectly govern its secretion. Importantly, in 
response to VEGF-A, the downstream signaling pathways of 
VEGFR2, as detected by the levels of phospho-VEGFR2 
(pTyr1175), phospho-Akt (pSer473), and phospho-ERK1/2, 
are significantly decreased in BCPAP-HA–-TRCP1 cells 
compared with BCPAP-EV cells (Fig. 8 C). In a similar fashion 
to the endothelial cells (Fig. 5, A and B), -TRCP1–expressing 
BCPAP cells exhibited significantly less migration in response 
to VEGF-A compared with the BCPAP-EV cells (Fig. 8,   
D and E). These results suggested that -TRCP1 plays a critical 
role in governing cellular migratory ability, presumably in part 
via regulating the stability of VEGFR2, in both human endo-
thelial and BCPAP thyroid cancer cell lines.
However, this could not explain why elevated VEGFR2 
expression in a subset of human thyroid cancer cells, by itself, 
could lead to increased angiogenesis which is typically associ-
ated with human endothelial cells. To address this question, 
we used a trans-well system of co-cultured BCPAP cells and 
human endothelial cells grown in the absence of serum to 
examine whether manipulation of the -TRCP1–VEGFR2 
signaling pathway in BCPAP cells could affect cellular migra-
tion of human endothelial cells (Fig. 9 A). Interestingly, we 
in the BCPAP cell line (Fig. 7 E) that can be reversed by treat-
ment with the proteasome inhibitor MG132 (Fig. 7 F), argu-
ing that -TRCP1 is a major negative regulator of VEGFR2 
abundance. Furthermore, there was no marked difference 
in  VEGFR2 mRNA levels between empty vector (EV) and 
-TRCP1–expressing BCPAP cells, indicating that the reg-
ulation of VEGFR2 abundance mainly occurs at the post-
transcriptional level (Fig. 7, G and H). These results indicate 
that in BCPAP (Fig. 7 A) or in poorly differentiated follicu-
lar thyroid cancer (FTC)–derived cells (FTC133; Fig. 7 B), 
-TRCP1 negatively regulates VEGFR2 abundance, possibly 
through a ubiquitination-dependent degradation pathway, as 
it does in human endothelial cells (Fig. 4). Importantly, we 
found that in human PTC clinical samples there is also a clear 
inverse correlation between -TRCP1 expression and sev-
eral angiogenesis markers (Fig. 7, C and D). This prompted us 
to further investigate whether elevated VEGFR2 expression 
in human PTC cells could affect the angiogenesis process of 
the surrounding endothelial cells.
To this end, we found that the BCPAP with elevated 
VEGFR2 levels secreted an increased amount of VEGF-A 
protein (2010 ± 580 pg/ml) compared with the ATC-de-
rived cells SW1736 and 8505C (517 ± 129 and 0.0 pg/ml, 
respectively) expressing low levels of VEGFR2 (Fig. 8 A), 
whereas ectopic expression of -TRCP1 significantly re-
duced the secreted VEGF-A (470 ± 98 pg/ml in BCPAP-
HA--TRCP1 cells compared with 967 ± 99 pg/ml in 
Figure 8.  -TRCP regulates PTC cell 
migration via regulating VEGFR2 protein 
levels and VEGF-A secretion in vitro.  
(A and B) The media from various cultured 
human thyroid cancer cell lines were col-
lected for ELISA analysis to determine the 
concentration of secreted VEGF-A. Data are 
representative of three independent experi-
ments. The error bars represent mean ± SD. 
**, P < 0.01; ***, P < 0.001. (C) Immunoblot 
analysis of BCPAP cells infected with EV or 
HA–-TRCP1–encoding lentiviral vectors. 
Where indicated, VEGF-A was added for 
15 min before harvesting. Data are repre-
sentative of two independent experiments. 
(D) EV or -TRCP–expressing BCPAP cells 
were exposed to 200 ng/ml VEGF-A where 
indicated. Cells were photographed after  
18 h. Bars, 5 µm. Data are representative  
of three independent experiments.  
(E) Quantitative measurement of migrated 
BCPAP cells shown in D. The error bars  
represent mean ± SD. ***, P < 0.001 (n = 3).JEM Vol. 209, No. 7 
Article
1301
cell migration compared with control (shGFP) BCPAP cells 
(Fig. 9, D and E). Overall, these results indicated that ele-
vated VEGFR2 expression in human thyroid cancer cells 
could not only regulate their own migratory ability via an 
autocrine mechanism but also regulate the migration of the 
surrounding human endothelial cells, presumably through a 
paracrine mechanism. The latter mechanism might offer a 
possible molecular mechanism for increased VEGFR2 ex-
pression that is frequently observed in various human cancers 
and its correlation with increased angiogenesis.
found that VEGFR2 levels in BCPAP cells play a critical 
role in determining migratory ability of the co-cultured 
HMVECs. Very few HMVECs migrated when they were co-
cultured with -TRCP1–expressing BCPAP cells compared 
with BCPAP-EV cells (Fig. 9, B and C). This is likely a result 
of the elevated secretion of VEGF-A from the BCPAP-EV 
cells because the use of VEGF-A blocking antibody could 
efficiently  abolish  cellular  migration  of  the  co-cultured 
HMVECs (Fig. 9, B and C). Furthermore,  VEGFR2 knockdown 
BCPAP (shVEGFR2) cells showed a significant decrease in 
Figure 9.  -TRCP regulates VEGFR2 protein levels in human PTC-derived cells, and thereby influences sensitivity to the VEGFR2 inhibitor 
sorafenib. (A and B) HMVECs were co-cultured with EV or -TRCP–expressing BCPAP cells in the presence or absence of VEGF-A antibody. (B) Cells were 
photographed after 44 h. Bars, 5 µm. Data are representative of three independent experiments. (C) Quantitative measurement of migrated BCPAP cells 
shown in B. The error bars represent mean ± SD. ***, P < 0.001 (n = 3). (D) Immunoblot analysis of the BCPAP cells infected with the indicated shRNA 
lentiviral vectors. Data shown is representative of two independent experiments. (E) BCPAP cells shown in D were exposed to 200 ng/ml VEGF-A where 
indicated. Recruited cells were photographed after 5 h. Bars, 5 µm. Data shown is representative of two independent experiments. (F) Various PTC cell 
lines were treated with the indicated concentrations of sorafenib. Cell viability was measured at 48 h. Data shown is representative of three independent 
experiments. The error bars represent mean ± SD. *, P < 0.05; ***, P < 0.001 (n = 3). (G) EV or HA–-TRCP1–expressing BCPAP cells were treated with the 
indicated concentrations of sorafenib. Cell viability was measured at 48 h. The error bars represent mean ± SD. **, P < 0.01; ***, P < 0.001 (n = 3).1302 -TRCP triggers VEGFR2 turnover | Wei et al.
thyroid cancer patients who fail to respond to the canonical 
treatment, there is generally neck recurrence and distance 
metastases leading to low survival rates; thus, rational tar-
geted therapies are needed (Baudin and Schlumberger, 
2007). The pathogenesis of squamous transformation of the 
thyroid gland remains unclear because the gland only con-
tains squamous epithelium under inflammatory processes or 
neoplasms (Kleer et al., 2000; Walvekar et al., 2006). Further-
more, of the targeted therapies that are used in clinical trials in 
patients with thyroid cancers, including PTC, sorafenib that 
targets VEGFR2 signaling has been considered a promising 
therapeutic intervention (Gupta-Abramson et al., 2008; Lam 
et al., 2010). However, recent clinical trials based on the use 
of sorafenib in patients with aggressive/metastatic/progressive 
thyroid cancers (including PTC or FTCs, etc.) have observed 
a partial response rate of 20% and a stable disease rate of 
53.3%. Furthermore, patients that histologically had an ATC 
showed a progressive disease (Gupta-Abramson et al., 2008), 
indicating that aggressive thyroid cancers may elicit unknown 
resistance mechanisms to sorafenib.
To this end, we have found for the first time that over-
expression of -TRCP1 markedly depleted VEGFR2 in the 
BCPAP cells (Fig. 7 E). More importantly, enhanced migration 
of HMVECs was observed when co-cultured with BCPAP-EV 
(control) cells. This migration was completely blocked in the 
presence of antibody to  VEGF-A (Fig. 8, D and E), suggesting   
that the VEGF-A secreted from BCPAP cells induced the 
HMVEC cell migration. In contrast, the migration of HMVECs   
was significantly reduced when -TRCP–overexpressing 
BCPAP cells were used in the co-cultured/transwell system 
(Fig. 9, A–C). These results suggested that by altering  VEGFR2 
and VEGF-A levels, -TRCP suppresses angiogenesis via a 
paracrine-mediated mechanism.
Overall, these results pointed to a prominent role for 
-TRCP in the negative regulation of  VEGFR2 levels in PTC 
cells. Notably, we also found an inverse correlation between 
the VEGFR2 expression levels and their pharmacological effi-
cacy/sensitivity to the VEGFR2 inhibitor sorafenib (Fig. 9, 
F and G). Poorly differentiated human PTC cells with elevated 
VEGFR2 are more sensitive to sorafenib. Therefore, our results 
suggest that defects in the -TRCP/CKI signaling pathway 
might contribute to increased VEGFR2 protein expression, 
as well as PTC cell migration and sensitivity to VEGFR2 
inhibitor, sorafenib. Furthermore, our work also provides 
a possible molecular basis for targeted use of VEGFR2 
inhibitors, such as sorafenib or other TKIs, to treat more 
aggressive PTCs refractory to conventional therapies based 
on -TRCP expression levels as a novel biomarker. Our   
results suggest that PTC patients with low expression levels 
of  -TRCP  may  respond  more  favorably  to  sorafenib 
treatment, whereas PTC patients with elevated -TRCP 
expression might be poor responders. As genomic loss of 
-TRCP has been identified in certain types of cancers 
(Frescas and Pagano, 2008), our results indicate that dys-
function in either -TRCP or CKI might lead to stabili-
zation of VEGFR2, which could result in hyperactivation of 
As recent studies suggest that oncogene addiction could 
be used as a rationale for targeted anti-cancer therapy (Weinstein 
and Joe, 2006), we wanted to understand whether expres-
sion levels of VEGFR2 in various human thyroid cancer 
cells correlate with their sensitivity to the VEGFR2 inhibi-
tor, sorafenib. Interestingly, we found that the BCPAP cell 
line that exhibited increased VEGFR2 protein expression 
showed increased sensitivity to sorafenib, compared with 
SW1736 and 8505C ATC-derived cell lines with much lower 
expression levels of VEGFR2 and corresponding higher levels 
of -TRCP1 (Fig. 9 F). At 3 µM sorafenib, the cell viability 
was significantly decreased in BCPAP cells, whereas no sig-
nificant decrease was observed in SW1736 and 8505C cells 
at this sorafenib concentration (Fig. 9 F). Because sorafenib 
has  been  proposed  as  an  efficient  inhibitor  of VEGFR2   
kinase, these results indicate that human thyroid cancer cell 
lines with high levels of VEGFR2, such as BCPAP, might be 
in part addicted to VEGFR2 activity/functions, and thereby 
be more sensitive to  VEGFR2 inhibitors including sorafenib. 
Consistent with this notion, we further showed that ectopic 
expression of -TRCP1, which efficiently reduced endoge-
nous VEGFR2 levels (Fig. 9 G), could significantly reduce 
BCPAP’s sensitivity to sorafenib. At 3 µM sorafenib con-
centration, the BCPAP-EV cell viability was significantly 
reduced when compared with a slight reduction of cell   
viability in BCPAP-HA–-TRCP1 cells (Fig. 9 G). Col-
lectively, these results identify a critical role of -TRCP1 in 
determining the cellular sensitivity and therapeutic efficacy of 
sorafenib treatment in human thyroid cancer cells. They fur-
ther suggest that thyroid cancer patients with low -TRCP1 
expression might respond better to the sorafenib (and maybe 
to other TKIs) treatment.
DISCUSSION
Here, we show for the first time a possible mechanism by 
which CKI-dependent phosphorylation of VEGFR2 at spe-
cific sites in its C-terminal tail triggers SCF-TRCP-mediated 
VEGFR2 ubiquitination and destruction. Importantly, our 
study demonstrated that -TRCP depletion leads to stabili-
zation of VEGFR2 in human endothelial cells as well as in 
human thyroid cancer cells, leading to increased sensitivity 
to VEGF-A–induced stimuli. Correspondingly, this stimuli 
increased cell migration and enhanced tube formation in 
-TRCP–depleted HMVECs. Consistent with the conclusions 
drawn from our in vitro cell-based assays, we also observed an 
increased number of branching vessels in zebrafish (Weinstein, 
2002) when -TRCP2 was specifically depleted by MO 
treatment (Fig. 6, A–F). Moreover, the increased formation of 
blood vessels was associated with increased VEGFR2 protein 
levels in -TRCP2 knockdown zebrafish. These findings in-
dicated a prominent role for -TRCP in regulating angio-
genesis, possibly through the timely destruction of VEGFR2.
Furthermore, we observed a strong inverse correlation be-
tween -TRCP1 and VEGFR2 in BCPAP thyroid cancer cell 
line (Fabien et al., 1994) as well as in primary PTC with squa-
mous metaplasia (Fig. 7, A and B). For poorly differentiated JEM Vol. 209, No. 7 
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vectors against Cullin-1 and Cullin-4A were gifts from J. Wade Harper 
(Harvard Medical School, Boston, MA).
Cell transfections for lentivirus (shRNA) or retrovirus production. 
5 × 105 HEK 293T cells were grown in 60-mm plates and transfected using 
Lipofectamine (Invitrogen) in OptiMEM (Invitrogen) for 48 h according to 
the manufacturer’s instructions. After infection, the cells were selected with 
1–2 µg/ml puromycin for 72 h to eliminate the uninfected cells before col-
lecting the whole cell lysates (WCLs) for the subsequent biochemical assays.
Suppression or overexpression techniques. Either lentiviral or retrovi-
ral infections (viral transductions) were performed as follows: 6 × 105 HEK 
293T cells were seeded in 60-mm dishes and cotransfected the next day with 
each lentivirus or retrovirus vector, along with helper plasmids (i.e., gag-pol 
and VSV-G were used for lentiviral infections). Media with progeny virus 
from transfected HEK 293T cells was collected every 24 h for 2 d, and then 
filtered with 0.45-µm filters (Millipore) and freshly used to transduce 293T, 
HeLa, HMVEC, and BCPAP cells overnight in the presence of 8 µg/ml 
Polybrene (Sigma-Aldrich). Finally, stable transduced cells were treated with 
2.5 µg/ml blasticidin or 1–2 µg/ml puromycin (Sigma-Aldrich) for selection. 
Gene or protein knockdown or overexpression in the transduced cells was 
confirmed by real-time RT-PCR and Western blot analysis. All assays were 
performed in triplicate.
Antibodies and reagents. Anti c-Myc, polyclonal anti-HA, anti-CKI 
(H-60), anti-CKI, anti-Cullin 1, anti–FLK-1 (A-3) AC, anti–-TRCP, anti-
CCM3, and anti–human VEGF-A antibodies were purchased from Santa 
Cruz Biotechnology, Inc. Anti-Cullin5 was from Bethyl Laboratories, Inc., 
and anti-Cullin4 (2699S) and anti–-TRCP (D13F10) antibodies were pur-
chased from Cell Signaling Technology. Anti-CKI antibody was purchased 
from BD. Anti-tubulin, polyclonal anti-FLAG, monoclonal anti-FLAG, per-
oxidase-conjugated anti–mouse secondary antibody, peroxidase-conjugated   
anti–rabbit secondary antibody, anti-Flag agarose beads, and anti-HA agarose 
beads were purchased from Sigma-Aldrich. Monoclonal anti-HA antibody was 
purchased from Covance. Anti-GFP antibody was obtained from Invitrogen. 
Anti-VEGFR1, anti-VEGFR2, anti-VEGFR3, anti–phospho-VEGFR2-1175,   
anti–phospho-AKT (ser473), anti–total-AKT1, anti-pERK1/2, and anti–
total-ERK1/2 antibodies were purchased from Cell Signaling Technology. 
Sorafenib was purchased from Enzo Life Sciences and  VEGF-A was obtained 
from Dr. Lawler’s laboratory.
Immunoblots and immunoprecipitation. Cells were lysed in EBC (50 mM 
Tris, pH 8.0, 120 mM NaCl, and 0.5% NP-40) buffer supplemented with 
protease inhibitors (Complete Mini; Roche) and phosphatase inhibitors 
(phosphatase inhibitor cocktail set I and II; EMD). The protein concentrations of 
the lysates were measured using a protein assay reagent (Bio-Rad Laboratories) 
on a DU-800 spectrophotometer (Beckman Coulter). The lysates were then 
resolved by SDS-PAGE and immunoblotted with the indicated antibodies. 
For immunoprecipitation, 20 h after transfection, cells were treated with   
10 µM MG132 overnight before harvesting for immunoprecipitation proce-
dures. 800 µg of protein lysates were incubated with the appropriate antibody 
(1–2 µg) overnight at 4°C, followed by the addition of carrier beads. Immuno-
complexes were washed five times with NETN buffer (20 mM Tris, pH 8.0, 
100 mM NaCl, 1 mM EDTA, and 0.5% NP-40) before being resolved by 
SDS-PAGE and immunoblotted with indicated antibodies.
Protein degradation analysis. Cells were plated into 6-cm tissue culture 
dishes 20 h before transfection. When cells reached an appropriate conflu-
ence, they were transfected with 2.0 µg HA-VEGFR2, along with 1.0 µg 
Flag--TRCP1 and 0.1 µg of a plasmid encoding GFP as an internal control, 
in the presence or absence of 0.4 µg Myc-CKI. For half-life studies, 20 µg/ml 
cycloheximide (CHX; Sigma-Aldrich) was added to the medium 40 h after 
transfection. At various time points thereafter, cells were lysed and protein con-
centrations were measured. 30 µg of the indicated WCLs were separated by 
SDS-PAGE and protein abundances were measured by immunoblot analysis.
the VEGF-A–VEGFR2 pathway that facilitates angiogenesis 
and cancer cell migration.
In summary, our study provides a possible molecular mech-
anism for the frequent elevation of VEGFR2 displayed in 
many types of human cancers. Therefore, drugs that activate the 
-TRCP and/or CKI signaling pathways to induce VEGFR2 
destruction could be used to treat various types of human can-
cers that are associated with increased angiogenesis. In contrast, 
the identification of both -TRCP and CKI as the upstream 
components involved in regulating VEGFR2 stability also pro-
vides the rationale for developing -TRCP and CKI inhibitors 
as potential novel drugs to induce angiogenesis. These pharma-
cological agents could be used to facilitate new blood vessel 
formation for the treatment of cardiovascular diseases, such 
as coronary artery disease or heart injury, that are frequently 
observed in the aged population.
MATERIALS AND METHODS
Cell culture. HeLa human cervical carcinoma and 293T human embryonic 
kidney cell lines were cultured in DME medium containing 10% FBS and 
antibiotics (streptomycin and penicillin). The HMVEC line was cultured in 
endothelial growth medium (EGM) containing 2% serum and 0.2% bovine 
brain extract (Shao and Guo, 2004). Human thyroid cancer cell lines: the 
BCPAP human thyroid cancer cell line harboring the BRAFV600E mutation 
was established from the primary tumor of a 76-yr-old woman with poorly 
differentiated PTC with squamous metaplasia (Fabien et al., 1994) and pro-
vided by G. Damante (University of Udine, Udine, Italy); and the 8505C 
human metastatic cell line (human ATC) was purchased from Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (German collection of 
microorganisms and cell culture) harboring the BRAFV600E mutation. The 
human metastatic ATC-derived cell line SW1736 harboring the BRAFV600E 
mutation was provided by N.E. Heldin (University of Uppsala, Uppsala, 
Sweden). The FTC133 human FTC-derived cell line and the FTC236 human 
metastatic FTC-derived cell line were provided by O.H. Clark (University   
of California, San Francisco Medical Center, San Francisco, CA). BCPAP, 
FTC133, and FTC236 cells were cultured in DME medium with 10% FBS 
and antibiotics. SW1736 and 8505C cells were cultured in RPMI medium 
containing 10% FBS and antibiotics.
Plasmids. pIRES-VEGFR2-HA was obtained from J. Huot and F. Houle 
(Laval University Cancer Research Center, Quebec, Canada). VEGFR2 
mutants were generated with the QuikChange XL Site-Directed Muta-
genesis kit (Agilent Technologies) according to the manufacturer’s instruc-
tions. Various VEGFR2 cDNAs were subcloned using the Pfu polymerase 
(Agilent Technologies) into the pGEX vector to create GST-VEGFR2 in 
frame fusion proteins. Short hairpin RNAs (shRNA lentivirus vectors), i.e., 
shRNA–-TRCP1,  shRNA–-TRCP1+2,  shRNA-GFP,  and  various 
CKI constructs were described previously (Jin et al., 2003; Shirogane et al., 
2005).  Myc–-TRCP1,  Myc–-TRCP2,  Myc–-TRCP1-R474A,  and 
HA–-TRCP1 constructs were described previously (Jin et al., 2003; Wu 
et al., 2003; Shirogane et al., 2005). sh-TRCP–resistant -TRCP1 cDNA 
was described previously (Inuzuka et al., 2010) and was subcloned into 
Blasticidin-encoding lentiviral vector obtained from Addgene. Myc-Cullin 1, 
Myc-Cullin 2, Myc-Cullin 3, Myc-Cullin 4A, and Myc-Cullin 5 con-
structs were gifts from J. DeCaprio (Dana-Farber Cancer Institute, Boston, 
MA). shRNA constructs against various CKI isoforms were obtained from 
J. Jin (The University of Texas Health Science Center, Houston, TX). 
Lentiviral shRNA constructs against GFP and CKI were obtained from 
W. Hahn (Dana-Farber Cancer Institute, Boston, MA). Lentiviral shRNA 
constructs against  VEGFR2 were obtained from Thermo Fisher Scientific, 
and the specific clone number TRCN0000001687 was used to effectively 
knock down VEGFR2 in HMVEC and BCPAP cell lines. shRNA lentiviral 1304 -TRCP triggers VEGFR2 turnover | Wei et al.
top of each well in serum-free medium. Therefore, these two types of cells 
were separated by the insert membrane. The secreted VEGF-A from the 
BCPAP cells (which were grown in the absence of serum) served as che-
moattractant to induce migration of HMVECs (Fig. 9 A-C). The assay was 
conducted in the presence or absence of 5–10 µg human VEGF-A antibody 
for 44 h, and the migrated HMVECs were photographed and quantified 
as described. In all assays, migrated cells were counted (number of cells/field 
or number of cells/well) using a 10 or 20× objective, and four fields were   
chosen per well with two well per each condition. Furthermore, migrated 
cells were also photographed using a camera attached to the microscope.
In vitro angiogenesis assay. The in vitro angiogenesis assays (tube forma-
tion assays) were performed as previously described (Ponce, 2001). In brief, 
control shGFP and sh-TRCP HMVECs (4 × 104/0.5 ml) in EGM medium 
containing 2% serum were seeded on Matrigel (BD) and treated with or 
without 100 ng/ml VEGF-A. After 5 h of incubation, cells were photo-
graphed using the camera attached to the microscope. The number of tubes 
was counted using a 10 or 20× objective and four fields were chosen per well 
with two wells per each condition.
Zebrafish  MO  knockdown  experiments. Zebrafish were maintained 
according to Institutional Animal Care and Use Committee (IACUC-
BIDMC) protocols. The MO sequences were used to target Fbxw11a 
(5-AGGTTTTGTCCTCCATCTCCGTCTC-3;  or  the  splice  form, 
5-GAAATACAACACACACCTTGAACAC-3) and Fbxw11b (5-ATT-
GTTGTTCTAGCTGAATCCAACC-3; or the splice form, 5-AAGAG-
CACCCAAACACTTACCATCT-3).  Control  and  knockdown  MOs 
specifically targeted to -TRCP2 were injected into wild-type or endo-
thelial reporter (Kdrl:EGFP and fli1a:EGFP) zebrafish at the one cell stage   
(three  independent  replicate  experiments  were  performed). At  72  h  after 
fertilization,  viability  counts  were  enumerated  and/or  embryos  were   
imaged by fluorescence microscopy using a microscope (Discovery; Carl Zeiss) 
to assess alterations in vascular development in two independent zebrafish 
reporter lines: Kdrl:EGFP (Cross et al., 2003) and fli1a:EGFP (Lawson and 
Weinstein, 2002). In situ hybridization and RT-PCR were conducted using 
standard zebrafish protocols (www.zfin.org). The following RT-PCR prim-
ers were used: fbxw11a forward 5-ACAAAACCCTGGAGCTGATG-3, 
and reverse 5-GTCCAGGAACGACAGGATGT-3; and fbxw11b forward 
5-CATTTTCACTGCGAGTTTCG-3, and reverse 5-TCAAAGAGCT-
GGATGCACAC-3. Anti-VEGFR2 antibody (Abcam) was used to detect 
endogenous VEGFR2 in zebrafish. This antibody was raised with synthetic 
nonphosphopeptide derived from human VEGFR2 around the phosphory-
lation site of tyrosine 1059 (P-D-YP-V-R), a region which shares a high 
degree of homology with the zebrafish VEGFR2 protein.
Cell viability assay. Human thyroid cancer cell lines (1 × 104 cells/well) 
were cultured in medium containing 0.5% serum and plated in a 96-well 
sterile culture plate. Cells were treated with or without various concentra-
tions of sorafenib for 48 h. Cell viability was measured using the CellTiter-
Glo Luminescent Cell Viability assay kit according to the manufacturer’s 
instructions (Promega).
ELISA. BCPAP, EV-BCPAP, HA--TRCP1-BCPAP, SW1736, and 
8505C thyroid cancer cells were cultured in 6-cm dishes with serum-free 
medium overnight. The next day, the medium was collected and secreted 
VEGF-A protein levels were determined by ELISA kit (R&D Systems) 
according to the manufacturer’s instructions.
Flow cytometry analysis. sh-GFP or sh--TRCP transduced HMVECs 
were serum starved overnight and then collected, fixed with 75% ethanol, 
and stained with propidium iodide for flow cytometry analysis according to 
Nucera et al., (2010) using FACS (BD) to assess sub-G1 cell populations.
Histological and immunohistochemical analysis. All tissue specimens 
were fixed with 10% buffered formalin phosphate and embedded in paraffin 
Real-time RT–PCR analysis. RNA was extracted with an RNeasy mini kit 
(QIAGEN), and the reverse transcription reaction was performed with the ABI 
TaqMan Reverse Transcription Reagents (N808-0234). After mixing the result-
ing template with VEGFR2 (Hs00911700_m1), -TRCP1 (Hs001182707_m1),   
or -TRCP2 (Hs00362667_m1) primers and TaqMan Fast Universal PCR 
Master Mix (4352042; Applied Biosystems), the real-time RT-PCR reaction 
was performed with the ABI-7500 Fast Real-time PCR system (Applied 
Biosystems). VEGF-A copies number/106 18S were assessed by absolute quan-
tification using real-time RT-PCR (Shih and Smith, 2005) using the VEGF-A 
and 18S primer sequences provided by the Multigene Transcriptional Profiling 
Core Facility (Center for Vascular Biology Research, Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, MA).
VEGFR2 binding assays. Binding to immobilized GST proteins was per-
formed as described previously (Wei et al., 2004). Where indicated, the 
GST-VEGFR2 proteins were incubated with CKI in the presence of ATP 
for 1 h before the binding assays.
In vitro kinase assay. CKI was purchased from New England Biolabs, 
Inc. The CKI in vitro kinase assays were performed according to the manu-
facturer’s instructions (New England Biolabs, Inc.). In brief, 5 µg of indicated 
GST fusion proteins were incubated with purified active CKI in the 
presence of 5 µCi -[32P]ATP and 200 µM cold ATP in the CKI reaction 
buffer for 30 min. The reaction was stopped by the addition of SDS-containing 
lysis buffer, resolved on SDS-PAGE, and detected by autoradiography 
(Inuzuka et al., 2010).
In vitro ubiquitination assay. The in vitro ubiquitination assays were per-
formed as described previously (Jin et al., 2005). To purify SCF-TRCP1 com-
plex, 293T cells were transfected with vectors encoding GST–-TRCP1, 
Myc–Cul-1, Myc-Skp1, and HA-Rbx1. The SCF-TRCP1 (E3) complexes 
were purified from the WCLs using GST-agarose beads. Before the in vitro 
ubiquitination assay, indicated GST-VEGFR2 proteins were incubated 
with purified, recombinant active CKI in the presence of ATP (with   
kinase reaction buffer as a negative control) at 30°C for 30 min. Afterward, 
the kinase reaction products were incubated with purified SCF-TRCP1 
(E3) complexes in the presence of purified, recombinant active E1, E2 
(UbcH5a and UbcH3), ATP, and ubiquitin at 30°C for 45 min. The reac-
tions were stopped by the addition of SDS-PAGE sample buffer and the 
reaction products were resolved by SDS-PAGE and probed with the in-
dicated antibodies (Inuzuka et al., 2010).
Cell migration assay and trans-well co-culture system. Migration 
assays were performed according to manufacturer’s instructions using cham-
bers (Corning) that did not contain Matrigel. In brief, shGFP- or sh-TRCP 
cells (2.5 × 104 HMVECs/0.5 ml) without serum were seeded into the   
insert. The bottom face of the filters (with 8-µm pore) were coated with type I 
collagen. 5% FBS in growth medium was added into the wells as a che-
moattractant. In brief, these trans-wells/chambers were used to study the ef-
fect of -TRCP knockdown on the migration of transduced HMVECs in 
the presence or absence of 30–100 ng/ml VEGF-A. The migration assay was 
performed for 5–18 h in culture and then inserts were fixed in methanol for 
2 min, stained with Giemsa for 30 min, washed in distilled water, and air 
dried. Additionally, shGFP or shVEGFR2 BCPAP cells were grown in 10% 
serum for 24 h, and then 1 × 105 cells/0.5 ml were seeded into the insert 
(in the presence or absence of 100 ng/ml human VEGF-A, added into the 
insert along with the cells) of the transwell and 5% FBS in growth medium 
was added into the wells as chemoattractant. Migration assay was run for 4 h. 
BCPAP cells (EV or HA--TRCP1) were cultured (2 × 104 cells/0.5 ml/
insert of transwell) were grown for 24 h with low serum (2%) and then 
serum-free overnight before migration assay. 200 ng/ml  VEGF-A was used as 
chemoattractant in the well. Migration assay was run for 18 h.
We also generated a trans-well cell co-culture system (Fig. 9 A). BCPAP 
cells (EV or HA--TRCP1) were cultured (2 × 104 cells/well) in 24-well 
plates. HMVECs (5 × 104 cells/0.5 ml) were placed in inserts and placed on JEM Vol. 209, No. 7 
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blocks. Histopathology evaluation was performed by an endocrine pathologist 
(P.M.  Sadow)  on  hematoxylin  and  eosin  (H&E)–stained  tissue  sections  of   
15 human thyroid carcinomas under the approval of Massachusetts General Hos-
pital IRB committee (P.M. Sadow, 2011P000013). These were visualized with 
a microscope (BX 41; Olympus) and a camera (Q COLOR 5 photo; Olympus). 
4-µm-thick sections of 10 formalin-fixed human thyroid carcinomas with   
squamous metaplasia foci (6 classical PTC, 1 PTC tall cell variant, 1 PTC diffuse 
sclerosing variant, 1 squamous cell carcinoma, and 1 poorly differentiated thyroid 
carcinoma) classified according to the World Health Organization (for squamous 
metaplasia features read Kleer et al., 2000). Tumor size was >0.4 cm (range: 0.4–
4.5 cm; mean: 1.6 cm). 4 out of 10 thyroid carcinomas showed extra thyroidal 
extension, 4 out of 10 thyroid carcinomas showed lymphovascular invasion, and 
4 out of 10 thyroid carcinomas showed neck lymph nodes metastasis (Table S1). 
These thyroid tumor tissues were used for immunohistochemical (IHC) proce-
dures. After baking overnight at 37°C, deparaffinization with xylene/ethanol and 
rehydration were performed. IHC was performed using the -TRCP (Santa 
Cruz  Biotechnology,  Inc.), VEGFR2  (2479;  Cell  Signaling Technology), 
VEGF-A (C1; Santa Cruz Biotechnology, Inc.), D2-40 (marker of lymphatic 
vessels; Covance), and CD31 (marker of endothelial cells; M20; Abcam) primary 
antibodies. The sections, treated in a pressure cooker for antigen retrieval (Biocare 
Medical), were incubated at 123°C in Citrate buffer (Target Retrieval Solution; 
DAKO), cooled, and washed with PBS. Antigen retrieval was performed for 
60 min at RT. The primary antibody was detected using a biotin-free second-
ary antibody (K4011; Envision system; DAKO) and incubated for 30 min. All 
incubations were performed in a humid chamber at room temperature. Slides 
were rinsed with PBS between incubations. Sections were developed using 
3,3-diaminobenzidine (DAB; Sigma-Aldrich) as a substrate and were counter-
stained with Mayer’s Hematoxylin. The immunohistochemical markers were 
assessed semi-quantitatively using the following scoring method: 0, negative; 
1+, 1–10% positive cells (low expression); 2+, 11–50% positive cells (moderate 
expression); and 3+, >50% positive cells (high expression).
Statistical analysis. Results were expressed as mean ± SD. Statistical com-
parisons were made using an unpaired Student’s t test and one way ANOVA 
(Excel; Microsoft). Densitometry analysis was performed using ImageJ soft-
ware (National Institutes of Health) and values were normalized to tubulin. 
Differences were considered statistically significant when P < 0.05.
Online supplemental material. Fig. S1 lists the DSG(XX)S phospho-
degron sequences in VEGFR2 recognized by -TRCP, as well as potential 
and predicted CKI-mediated phosphorylation sites in VEGFR2. Fig. S2 
presents zebrafish embryo viability data after treatment with MOs that 
target -TRCP2. Fig. S3 lists the -TRCP–recognizable DSG-like canon-
ical degron consensus in VEGF-A among various species. Table S1 lists the 
-TRCP1 protein expression levels and angiogenesis markers in human 
thyroid cancers. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20112446/DC1.
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